Skip to main content
European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Zawartość zarchiwizowana w dniu 2024-05-29

Development of a bioartificial pancreas for type I diabetes therapy

Cel

Four to five million people in Europe and about 80 million worldwide suffer from type 1 diabetes (insulin-dependent), characterized by a deficiency in insulin secretion resulting in hyperglycaemia responsible for debilitating long-term complications (coronary diseases, acquired blindness, chronic renal failures). Recently developed immunosuppressive protocols improved the success of humanallogenic pancreatic islets transplantation. However, such transplantation has severe limitations: the number of available donors and the potential toxicity of the immunosuppressive treatments. To avoidimmunosupression, islets could be encapsulated to protect them from the attack of the immune system and thus from rejection.
This project intends to develop, improve and validate an efficient reliablebioartificial pancreas for human application. To achieve this ambitious goal, various disciplines reintegrated in a true task force of basic and clinical researchers with leading expertise in experimental diabetes and advanced modern material technologies to develop an effective approach for the treatment of type 1 diabetes. The proposed approach takes into account the far-reaching advances in the modernnanosize technology, which are of utmost importance for the success of this challenge. To canny out the project to a successful achievement, the consortium gathers a multidisciplinary group of leading European scientists with complementary competencies, spending from biomaterials to tissue engineering, and high-tech Sees. This transactional approach provides convincing solutions to bypass the limitations of traditional treatments of this disease. That proposal fits perfectly within the scope of Priority Nan technologies and Nan sciences, 3.4.1 in particular Biotechnologies-biotechnologies, 3.4.1.2.Furthermore the proposal addressed also the 3.4.1.5 Application in areas such as health and medical systems, chemistry, energy, optics, food and environment.

Zaproszenie do składania wniosków

FP6-2002-NMP-1
Zobacz inne projekty w ramach tego zaproszenia

Koordynator

CENTRE EUROPEEN D'ETUDES DU DIABETE
Wkład UE
Brak danych
Adres
Hopitaux Universitaires de Strasbourg, Boulevard Rene Leriche
STRASBOURG
Francja

Zobacz na mapie

Koszt całkowity
Brak danych

Uczestnicy (13)